Pfizer
FDA panel votes against Pfizer’s tanezumab for osteoarthritis pain
A joint FDA advisory committee has rejected a risk mitigation proposal for Pfizer and Eli Lilly’s osteoarthritis (OA) drug tanezumab,…
Pfizer reports data from tafamidis’ rare heart disease trial
A new phase III clinical trial has demonstrated that Pfizer’s tafamidis drug can lower the risk of death in patients…
BioNTech signs $425m flu vaccine deal with Pfizer
German biopharmaceutical company BioNTech has signed a research and development (R&D) agreement with Pfizer for the development of mRNA-based vaccines…
Pfizer’s Xeljanz secures marketing authorisation in Europe
Pfizer has received approval from the European Commission (EC) to market Xeljanz (tofacitinib citrate) for the treatment of adults suffering…
Pfizer to build $465m injectable medicines facility in US
Pfizer has revealed plans to invest $465m for the construction of an advanced sterile injectable pharmaceutical manufacturing plant at Portage…
Pfizer to split into three businesses
Pfizer has revealed plans to reorganise into the company into three different businesses, namely Innovative Medicines, Established Medicines, and Consumer…